Cure8 research brief
The study links symptom trajectories during the first year of biologic treatment to endoscopic remission, suggesting that week 20 symptom assessment may help predict long-term outcomes for people with UC on biologics.
Adult UC patients on biologics; clinicians managing biologic therapy; researchers studying treatment response and biomarkers.
The study combined partial Mayo score records from five clinical trials to model symptom trajectories over 52 weeks and linked those patterns to endoscopic and histologic remission rates.
Patients whose symptoms improved rapidly had the highest rates of mucosal healing by one year, while those in relapse-fluctuation or slow-improvement groups had lower probabilities of remission.
The authors suggest that assessing clinical activity around week 20 may help predict longer-term outcomes and guide treatment decisions, but this is based on trial data pooled for trajectory analysis rather than a randomized comparison of management strategies.
Structured content depth: abstract — the curation summarizes findings reported in the article abstract and pooled-trial analysis; it does not represent a full independent review of the complete study.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
If validated, an early drop in fecal calprotectin could help identify patients on biologic therapy who are likely to achieve mucosal healing without waiting for invasive endoscopy, allowing earlier decisions about...
If confirmed, a simple blood marker (NLR) plus biopsy results could help identify UC patients at higher risk of relapse despite endoscopic improvement, which might guide monitoring or treatment choices.
Blood markers that correlate with endoscopic healing could help track inflammation noninvasively and may reduce the frequency of endoscopy if validated. For people with IBD, better blood-based tools could make monitoring...
